Get your patients moving, even in the adjuvant setting! Of course, a lot of bias is possible here, but there was nearly a 10% difference in cure at three years.
Guideline of the month — ASCO guidance on mCRC. Many interesting points made.
More may not always be better. Adjuvant Nivo q2-weeks + Ipi q6-weeks was not better than Nivo q4 weeks in reducing recurrences in fully resected stage III-IV melanoma.
Phase II/III study of weekly docetaxel+RT vs. RT alone in cis-ineligible patients. This study was done in India, where oral cancers are an epidemic and possibly biologically unique, as most are related to the use of oral tobacco + betel nut products. >70% of patients were stage IVA / IVB, and HPV was only positive in 4% of patients. Still, the survival benefit was sizeable, and the treatment was tolerable. This is a good option for cis-ineligible HPV-neg patients with bulky disease.
Another EGFR inhibitor beating chemotherapy in EGFR mutated NSCLC in the adjuvant setting.
Two words: better and safer.
Bispecific antibody, still with toxicity though, although pts had pretreatment with obinutumzumab to mitigate CRS. Response rate 35% in pts who received CAR-T therapy.
A small study but seems promising, for some patients surgery may not be needed after neoadjuvant therapy ( Triple negative and HER-2 neu positive). Colorectal surgeons in Orlando are avoiding surgery in some pts who respond to Neoadjuvant chemotherapy. Need more trials though.
This trial is an eye opener, I know many practice this, but this trial shows that treating women with confirmed thrombophilia and a history of miscarriages with anticoagulation during pregnancy DOES NOT IMPROVE OUTCOME OF LIVE BIRTHS compared to surveillance.
Seems like maintenance month, I believe we are all practicing this, but confirmation of the benefit of maintenance PARP inhibitors in ovarian ca even in those without HRD.